Furthermore, we established CRC cells with a BRAF mutation using a parental DiFi CRC cell line with no BRAF mutations to investigate whether the occurrence of this BRAF mutation affects the efficacy of the TDB hEx3. Here, BRAF is linked to colorectal carcinoma.